Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity

Abstract

Purpose Pancreatic cancer (PC) is the fourth cause of death from cancer in the western world. Majority of patients present with advanced unresectable disease responding poorly to most chemotherapeutic agents. Chemotherapy for PC might be improved by adjusting it to individual genetic profiles. We attempt to identify genetic predictors of chemosensitivity to broad classes of anticancer drugs. Experimental Design Using a panel of genetically defined human PC cell lines, we tested gemcitabine (anti-metabolite), docetaxel (anti-microtubule), mitomycin C (alkylating), irinotecan (topoisomerase I inhibitor), cisplatin (crosslinking), KU0058948 (Parp1 inhibitor), triptolide (terpenoid drug) and artemisinin (control). Results All PC cell lines were sensitive to triptolide and docetaxel. Most PC cells were also sensitive to gemcitabine and MMC. The vast majority of PC cell lines were insensitive to cisplatin, irinotecan, and a Parp1 inhibitor. However, individual cell lines were often sensitive to these compounds in unique ways. We found that DPC4/SMAD4 inactivation sensitized PC cells to cisplatin and irinotecan by 2–4 fold, but they were modestly less sensitive to gemcitabine. PC cells were all sensitive to triptolide and 18% were sensitive to the Parp1 inhibitor. P16/CDKN2A inactivated PC cells were 3–4 fold less sensitive to gemcitabine and MMC. Conclusions Chemosensitivity of PC cells correlated with some specific genetic profiles. These results support the hypothesis that genetic subsets of pancreatic cancer exist, and these genetic backgrounds may permit one to personalize the chemotherapy of PC in the future. Further work will need to confirm these responses and determine their magnitude in vivo.

Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines

“…Several reports documenting gemcitabine sensitivity of PDA cell lines show higher induction of apoptosis following chemotherapeutic treatment than prior to treatment, but these studies involve cells treated for 48 to 72 h and seeded at densities ranging from 5 to 15 times lower than in the present study (77)(78)(79). As our study was concerned with the ability of influenza virus to induce apoptosis following infection at a high MOI, we chose to study the response over a period of 24 h, starting with those of confluent monolayers, to monitor CPE following infection.…”

Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment

“…Cytotoxicity of cisplatin in pancreatic cancer cell lines was positively correlated with MAP4K2 expression, whereas NLRC4 deficiency may lead to radio-resistance of the respective tumor [69, 70]. Similarly p53 dysfunction results in resistance to radiotherapy and chemotherapy, including drugs widely used in ONB like etoposide [71].…”

The genetic classification of pancreatic neoplasia

“…For example, in vitro studies have suggested that genetic testing may even be useful to preselect patients for treatment with chemotherapy agents [61]. Tumors harboring Fanconi anemia pathway gene mutations (such as BRCA1, BRCA2, and PALB2 mutations) and tumors harboring ATM mutations are examples of potential individualized treatment targets.…”